Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

Inclusion Criteria:

1. Written informed consent and legal representative's permission for studyparticipation obtained prior to beginning of participation in the study.

2. Age ≥6 to <18 years old.

3. Established diagnosis of active moderate-to-severe plaque psoriasis defined as aPASI score ≥ 10, body surface area (BSA) involvement of ≥10% and PGA score ≥ 3 onlyor with concomitant psoriatic arthritis.

4. Failure or intolerance of prior psoriasis treatment.

5. Patient was prescribed with secukinumab within 4-16 weeks before inclusion.

6. Decision for secukinumab prescription was made by the attending physician accordingto the approved national label during routine clinical practice, regardless of thisnon-interventional study conduct.

Exclusion Criteria:

1. Known or suspected severe hypersensitivity for secukinumab, formulation excipients,or injection device components (i.e., latex).

2. History of chronic recurrent infection.

3. Clinically significant infection exacerbation, including active tuberculosis.

4. Age <6 years or ≥18 years.

5. Pregnancy and breastfeeding.

6. Patients participating in parallel in an interventional clinical trial.

7. Patients participating in parallel in other Novartis-sponsored non-interventionalstudy generating primary data for secukinumab.

8. Patients within the safety follow-up phase of interventional study.

9. Active inflammatory bowel disease at inclusion.

10. Patients who received any vaccine within 4 weeks prior to secukinumab initiation.

11. Any medical or psychological condition in the investigator's opinion which mayprevent the study participation.